Skip to main content
. 2022 Jun 21;13:890073. doi: 10.3389/fimmu.2022.890073

Figure 6.

Figure 6

Targeted therapy to PI3K pathway ameliorated the abnormal B cell phenotypes in APDS patients. The peripheral blood from HC (n=8), the patients who had not been treated (n=3) and those who received targeted therapy (n=5) was analyzed for the percentages of different B cells subsets by flow cytometry and serum IgM by ELISA. P values were calculated by one-tailed unpaired t-test.